SBRT Well Tolerated, Effective for Primary Lung Neuroendocrine Tumor Physician's Weekly, 24 Feb 2023 THURSDAY, Feb. 23, 2023 (HealthDay News) — For patients with primary lung neuroendocrine tumor (LNET), stereotactic body…